Sales Nexus CRM

SS Innovations Appoints Sarah Romano as CFO to Drive Global Expansion and FDA Approval Pursuit

By FisherVista
SS Innovations International (NASDAQ: SSII) has appointed Sarah Romano as CFO, bringing over two decades of medtech finance experience to lead financial operations amid global expansion and pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
SS Innovations Appoints Sarah Romano as CFO to Drive Global Expansion and FDA Approval Pursuit

SS Innovations International, Inc. (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Based in the United States, Romano brings more than two decades of finance leadership experience in the medical technology and life sciences sectors and will help lead the company’s financial operations as it advances its global expansion strategy, including pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.

Most recently, Romano served as chief financial officer of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting and investor relations.

The appointment comes as SS Innovations aims to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.

Romano’s experience in raising capital and managing financial operations in the medical technology sector is likely to be instrumental as SS Innovations pursues FDA approval and global expansion. Her track record includes raising more than $100 million through public and private financings, which could help the company fund its regulatory and commercial milestones.

The full press release is available at https://ibn.fm/pAqlP. For more information about SS Innovations, visit the company’s newsroom at https://ibn.fm/SSII.

FisherVista

FisherVista

@fishervista